Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY:JNJ)

155.40 +0.19 (+0.12%)
Official Closing Price Updated: 4:10 PM EDT, Jun 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Johnson & Johnson

< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
99 100 Next >
Johnson & Johnson Death Cross: Stock Stumbles Despite Pipeline Promise
Johnson & Johnson (NYSE:JNJ) enters bearish pattern, death cross, but strong dividends & strategic moves in dermatology provide long-term appeal. 
Via Benzinga
The Smartest Dividend Stocks to Buy With $1,000 Right Now
Via The Motley Fool
10 Buy And Hold Forever Dividend Stocks
The following 10 stocks represent Dividend Kings that can continue to raise their dividends for decades to come. 
Via Talk Markets
Topics Stocks / Equities
Top 7 Blue-Chip Stocks With The Best Return Potential Going Into 2025
The year 2024 saw the U.S. stock market make new records, with major indices breaching key milestones. While many stocks witnessed a stellar rally this year, analysts still expect some blue-chip... 
Via Benzinga
Johnson & Johnson Options Trading: A Deep Dive into Market Sentiment
Via Benzinga
The Analyst Landscape: 15 Takes On Johnson & Johnson
Via Benzinga
Why NYSE:JNJ is a Top Pick for Dividend Investors.
Exploring JOHNSON & JOHNSON (NYSE:JNJ)'s dividend characteristics. 
Via Chartmill
Give Yourself the Gift That Will Keep On Giving in 2025 and Buy These 3 Top Dividend Stocks
Via The Motley Fool
The Options Market Is Pointing Us At Four Dividend Stocks Right Now
It’s a good idea to look at stocks that can give us what we need in the absence of a rally. 
Via Talk Markets
Topics Bonds Commodities Stocks / Equities
5 Lowest Volatility Dividend Stocks
Here are five dividend-paying stocks in the S&P 500 with the lowest standard deviation of daily returns over the past five years. 
Via Talk Markets
Topics Stocks Stocks / Equities
Exposures US Equities
Your Healthcare Costs are Soaring! US Spending Reached $5 Trillion In 2023 with Major Increase in Obesity and Diabetes Drugs, Hospital Services
U.S. healthcare spending grew 7.5% to $4.9 trillion in 2023, with hospital care and prescription drugs driving costs. Private insurance accounted for 30% of total spending. 
Via Benzinga
The Smartest Dividend Stocks to Buy With $500 Right Now
Via The Motley Fool
FDA Rejects Johnson & Johnson's Injectable Version Of Approved Drug For Lung Cancer
The FDA delays Johnson & Johnson's SC amivantamab approval for NSCLC over facility inspection issues, unrelated to product safety or efficacy 
Via Benzinga
Exposures Product Safety
Drug Price Hikes Unsupported By Evidence Cost US $815 Million: ICER Report
ICER's 2023 report highlights five drugs with unsupported price increases, leading to $815 million in excess costs for U.S. payers. Discover key findings and trends. 
Via Benzinga
Johnson & Johnson to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
From Johnson & Johnson
Via Business Wire
These Are the 5 Worst-Performing Stocks in the Dow Jones Industrial Average With 2024 Almost Over
Via The Motley Fool
Topics Stocks
Exposures US Equities
Jim Cramer Says This CEO 'Built An Amazing Company,' Recommends Buying Netflix
When asked about Advanced Micro Devices, Cramer asks: "But can we just remember Lisa Su has built an amazing company?" 
Via Benzinga
Jim Cramer Bullish On Netflix Nearing $1,000 And AMD's 'Cheap' Valuation Despite Nvidia Dominance
Jim Cramer expressed strong buying conviction for Netflix Inc. during Wednesday's Lightning Round on "Mad Money," as the streaming giant's shares traded near $934 amid broader tech market strength. 
Via Benzinga
Elon Musk's Net Worth Surpasses Market Cap Of US Giants Like BofA, Johnson & Johnson, Salesforce, Chevron, Coca-Cola And More: Only 25 Companies Have Higher Market Cap
Only 25 listed companies have a higher market capitalization than Elon Musk's skyrocketing net worth. 
Via Benzinga
GSK's Blood Cancer Drug Shows Improved Survival Compared To Johnson & Johnson's Darzalex
GSK's Blenrep combo demonstrates significant survival benefits and improved efficacy in relapsed multiple myeloma compared to Darzalex combo. 
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Johnson & Johnson to Host Investor Conference Call on Fourth-Quarter Results
From Johnson & Johnson
Via Business Wire
Arcellx And Legend Bio Trade Jabs In Multiple Myeloma. But Only One Pulls Ahead.
The companies held competing events on Sunday to discuss their multiple myeloma treatments. 
Via Investor's Business Daily
Coca-Cola cs. Procter & Gamble: Which Is the Better Dow Dividend King Stock to Buy Before the End of the Year?
Via The Motley Fool
Topics Stocks
Exposures US Equities
Top Analyst Reports For Home Depot, Johnson & Johnson & Salesforce
Today's Research Daily features new research reports on 16 major stocks, including The Home Depot, Inc., Johnson & Johnson, and Salesforce, Inc., as well as two micro-cap stocks, Preformed Line... 
Via Talk Markets
Topics Stocks / Equities
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Celebrating innovation happens from the inside out
(BPT) - For more than a century, Johnson & Johnson has been synonymous with innovation in science and medicine by moving the needle in building a world where complex diseases are prevented and cured,... 
Via Brandpoint
Ray Dalio's Bridgewater Adds Broadcom, Apple, SMCI In Q3, While Offloading Stake In AI Giant Nvidia And Other Big Tech Companies
Bridgewater Associates, the world's biggest hedge fund, sold top AI-linked stocks like Nvidia, Alphabet, Microsoft, Amazon, and Johnson & Johnson. 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
3 Fantastic Dividend Stocks to Buy Sooner Rather Than Later
Via The Motley Fool
Bristol-Myers Squibb Files Lawsuit Against US Agency For Overreach In 340B Drug Pricing Program
Bristol Myers Squibb sues HRSA, claiming its rejection of a rebate model for 340B pricing violates federal law. The lawsuit highlights concerns over program abuse and regulatory overreach. 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.